Cargando…

Type I Interferon Pathway-Related Hub Genes as a Potential Therapeutic Target for SARS-CoV-2 Omicron Variant-Induced Symptoms

Background: The global pandemic of COVID-19 is caused by the rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of SARS-CoV-2 Omicron variant infection varies from asymptomatic to severe disease with diverse symptoms. However, the underlying mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhiwei, Xue, Mingshan, Wu, Ziman, Liu, Ze, Yang, Qianyue, Hu, Jiaqing, Peng, Jiacong, Yu, Lin, Sun, Baoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458681/ https://www.ncbi.nlm.nih.gov/pubmed/37630661 http://dx.doi.org/10.3390/microorganisms11082101

Ejemplares similares

SARS-CoV-2 omicron variant: the black swan of microbiology
por: Cheng, Zhangkai J., et al.
Publicado: (2022)

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
por: Shalamova, Lyudmila, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
por: Bojkova, Denisa, et al.
Publicado: (2022)

Bioactivity Determination of Native and Variant Forms of Therapeutic Interferons
por: Larocque, Louise, et al.
Publicado: (2011)

Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron
por: Chong, Zhenlu, et al.
Publicado: (2022)

Interferon-α-2b Nasal Spray for Treating SARS-CoV-2 Omicron Variant-Infected Children
por: Zhou, Jianguo, et al.
Publicado: (2023)

Reproduction Number of the Omicron Variant Triples That of the Delta Variant
por: Du, Zhanwei, et al.
Publicado: (2022)

Duration of infectious shedding of SARS-CoV-2 Omicron variant and its relation with symptoms
por: Keske, Şiran, et al.
Publicado: (2023)

The emergence of the Omicron variant
por: Toovey, Oliver T.R., et al.
Publicado: (2022)

Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant
por: Sun, Yamin, et al.
Publicado: (2022)

Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
por: Alam, Mohammad Shah
Publicado: (2023)

SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant
por: Laine, Larissa, et al.
Publicado: (2022)

Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters
por: Yuan, Lunzhi, et al.
Publicado: (2022)

Heterogeneity of the Omicron variant in Senegal
por: Diédhiou, Cyrille Kouligueul, et al.
Publicado: (2022)

Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant
por: Wang, Wei Bu, et al.
Publicado: (2023)

Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient’s symptoms
por: Zhang, Peiyan, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2
por: Begum, Rahima, et al.
Publicado: (2022)

Type I Interferon: Potential Therapeutic Target for Psoriasis?
por: Yao, Yihong, et al.
Publicado: (2008)

Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms — China, December 2022–February 2023
por: Fu, Di, et al.
Publicado: (2023)

Immunological and metabolic characteristics of the Omicron variants infection
por: Geng, Jiejie, et al.
Publicado: (2023)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Therapeutics to tackle Omicron outbreak
por: Chavda, Vivek P, et al.
Publicado: (2022)

Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands
por: Petersen, Maria Skaalum, et al.
Publicado: (2022)

Longitudinal observation of viral load in patients infected with Omicron variant and its relationship with clinical symptoms
por: Zhou, Kai, et al.
Publicado: (2023)

WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub of Tumorigenesis and a Novel Therapeutic Target
por: Zhang, Zhiwei, et al.
Publicado: (2023)

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
por: Tao, Kaiming, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Aktuelle Informationen zur Omicron-Variante
por: Hasibeder, Walter
Publicado: (2022)

Omicron: a mysterious variant of concern
por: Gowrisankar, A., et al.
Publicado: (2022)

Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
por: Chong, Zhenlu, et al.
Publicado: (2022)

Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study
por: Xu, Nan, et al.
Publicado: (2022)

Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections
por: Woo, Marcel S, et al.
Publicado: (2023)

A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China
por: Cai, Jianpeng, et al.
Publicado: (2023)

Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20
por: Liu, Mingtao, et al.
Publicado: (2022)

Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
por: Nchioua, Rayhane, et al.
Publicado: (2023)

Correction: Type I Interferon: Potential Therapeutic Target for Psoriasis?
por: Yao, Yihong, et al.
Publicado: (2009)

ERC-BiP Functional Protein Pathway for Assessing Endoplasmic Reticulum Stress Induced by SARS-CoV-2 Replication after Cell Invasion
por: Xue, Mingshan, et al.
Publicado: (2023)

Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
por: Relan, Pryanka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b5vqd5ps4alf2thc693npfak23